beyond
schedules
second
fiscal
quarter
financial
results
conference
call
webcast
garden
city
globe
newswire
beyond
air
nasdaq
xair
medical
device
biopharmaceutical
company
focused
developing
inhaled
nitric
oxide
treatment
patients
respiratory
conditions
including
serious
lung
infections
pulmonary
hypertension
gaseous
gno
treatment
solid
tumors
tumor
metastases
today
announced
report
financial
results
second
fiscal
quarter
ended
september
wednesday
november
company
management
team
scheduled
host
conference
call
webcast
pm
eastern
time
day
conference
call
webcast
wednesday
november
pm
et
domestic
international
passcode
webcast
http
beyond
air
inc
beyond
air
medical
device
biopharmaceutical
company
developing
revolutionary
generator
delivery
system
uses
generated
ambient
air
deliver
precise
amounts
lungs
potential
treatment
variety
pulmonary
diseases
generate
ppm
delivery
either
continuously
fixed
amount
time
ability
either
titrate
dose
demand
maintain
constant
dose
company
currently
applying
therapeutic
expertise
develop
treatments
pulmonary
hypertension
various
settings
addition
treatments
respiratory
tract
infections
effectively
addressed
current
standards
care
beyond
air
currently
advancing
revolutionary
clinical
trials
treatment
severe
lung
infections
nontuberculous
mycobacteria
ntm
additionally
beyond
air
using
concentrations
proprietary
delivery
system
target
certain
solid
tumors
setting
information
visit
contacts
steven
lisi
chief
executive
officer
beyond
air
slisi
maria
yonkoski
head
investor
relations
beyond
air
myonkoski
